FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136806177> ?p ?o ?g. }

• W3136806177 endingPage "383" @default.
• W3136806177 startingPage "372" @default.
• W3136806177 abstract "Intralipid, a clinically used lipid emulsion, was reportedly utilized as one strategy to suppress off-target delivery of anticancer nanomedicines; Intralipid also effectively improved drug delivery to tumors and produced better therapeutic effects. However, the mechanisms involved—the why and how—in Intralipid's facilitation of delivery of nanomedicines to tumors have not yet been reported in detail. In this study, we investigated Intralipid and discovered the beneficial effects of Intralipid pretreatment when using three anticancer nanomedicines, including the clinically approved drug doxorubicin (Doxil). Intralipid pretreatment induced a 40% reduction in liver uptake of a polymeric nanoprobe used in photodynamic therapy as well as a 1.5-fold-increased nanomedicine accumulation in tumors. This increased accumulation consequently led to significantly better therapeutic effects, and this finding was validated by using Doxil. As an interesting result, Intralipid pretreatment significantly prolonged the plasma half-life of nanomedicines in normal healthy mice but not in tumor-bearing mice, which suggests that tumors become an alternative route of nanomedicine delivery when liver delivery is suppressed. Also, we found markedly increased tumor blood flow, as measured by fluorescence angiography, and significantly lower blood viscosity after Intralipid pretreatment. All our results together indicate that Intralipid treatment not only suppressed off-target nanomedicine delivery by the reticuloendothelial system, but more important, it enhanced nanomedicine delivery to tumors by improving tumor blood flow, which is key to satisfactory drug delivery via the enhanced permeability and retention effect. Significantly better therapeutic outcomes were thus achieved by the strategy of combining utilization of nanomedicines and Intralipid pretreatment. Off-target delivery to organs such as the liver and obstructed tumor blood flow as is often seen in advanced cancers are major barriers to the therapeutic efficacy of anticancer nanomedicines. Intralipid has been shown effective for suppressing nanomedicine accumulation in the liver, resulting in improved anticancer effects. Unraveling the mechanisms involved in this process will be greatly helpful for the clinical application of anticancer nanomedicines. We reported here that Intralipid could also significantly increase tumor delivery of nanomedicine, which is beneficial for improving tumor blood flow and lowering blood viscosity. To our knowledge, this is the first study to investigate the role of Intralipid in this regard. This knowledge provides a solid rationale for the use of Intralipid in combination with anticancer nanomedicines." @default.
• W3136806177 created "2021-03-29" @default.
• W3136806177 creator A5000236190 @default.
• W3136806177 creator A5009753049 @default.
• W3136806177 creator A5045632932 @default.
• W3136806177 creator A5055760559 @default.
• W3136806177 creator A5061590219 @default.
• W3136806177 creator A5065773217 @default.
• W3136806177 creator A5066624795 @default.
• W3136806177 creator A5080816054 @default.
• W3136806177 creator A5090520778 @default.
• W3136806177 date "2021-05-01" @default.
• W3136806177 modified "2023-10-04" @default.
• W3136806177 title "Unraveling the role of Intralipid in suppressing off-target delivery and augmenting the therapeutic effects of anticancer nanomedicines" @default.
• W3136806177 cites W1985241728 @default.
• W3136806177 cites W1989230986 @default.
• W3136806177 cites W2002015794 @default.
• W3136806177 cites W2013119249 @default.
• W3136806177 cites W2025919388 @default.
• W3136806177 cites W2027259992 @default.
• W3136806177 cites W2038882972 @default.
• W3136806177 cites W2056916650 @default.
• W3136806177 cites W2075387097 @default.
• W3136806177 cites W2078516817 @default.
• W3136806177 cites W2084335209 @default.
• W3136806177 cites W2087414776 @default.
• W3136806177 cites W2092527323 @default.
• W3136806177 cites W2096852130 @default.
• W3136806177 cites W2100090751 @default.
• W3136806177 cites W2126579954 @default.
• W3136806177 cites W2149957781 @default.
• W3136806177 cites W2153831697 @default.
• W3136806177 cites W2176120634 @default.
• W3136806177 cites W2331177167 @default.
• W3136806177 cites W2515394036 @default.
• W3136806177 cites W2761903020 @default.
• W3136806177 cites W2799710201 @default.
• W3136806177 cites W2806123710 @default.
• W3136806177 cites W2891557077 @default.
• W3136806177 cites W2906175764 @default.
• W3136806177 cites W2960056561 @default.
• W3136806177 cites W2985676530 @default.
• W3136806177 cites W3008198143 @default.
• W3136806177 cites W3035335179 @default.
• W3136806177 doi "https://doi.org/10.1016/j.actbio.2021.03.044" @default.
• W3136806177 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33774199" @default.
• W3136806177 hasPublicationYear "2021" @default.
• W3136806177 type Work @default.
• W3136806177 sameAs 3136806177 @default.
• W3136806177 citedByCount "7" @default.
• W3136806177 countsByYear W31368061772021 @default.
• W3136806177 countsByYear W31368061772022 @default.
• W3136806177 countsByYear W31368061772023 @default.
• W3136806177 crossrefType "journal-article" @default.
• W3136806177 hasAuthorship W3136806177A5000236190 @default.
• W3136806177 hasAuthorship W3136806177A5009753049 @default.
• W3136806177 hasAuthorship W3136806177A5045632932 @default.
• W3136806177 hasAuthorship W3136806177A5055760559 @default.
• W3136806177 hasAuthorship W3136806177A5061590219 @default.
• W3136806177 hasAuthorship W3136806177A5065773217 @default.
• W3136806177 hasAuthorship W3136806177A5066624795 @default.
• W3136806177 hasAuthorship W3136806177A5080816054 @default.
• W3136806177 hasAuthorship W3136806177A5090520778 @default.
• W3136806177 hasBestOaLocation W31368061771 @default.
• W3136806177 hasConcept C102652120 @default.
• W3136806177 hasConcept C136229726 @default.
• W3136806177 hasConcept C141071460 @default.
• W3136806177 hasConcept C15083742 @default.
• W3136806177 hasConcept C155672457 @default.
• W3136806177 hasConcept C171250308 @default.
• W3136806177 hasConcept C185154212 @default.
• W3136806177 hasConcept C192562407 @default.
• W3136806177 hasConcept C19831878 @default.
• W3136806177 hasConcept C2776694085 @default.
• W3136806177 hasConcept C2779820397 @default.
• W3136806177 hasConcept C2780035454 @default.
• W3136806177 hasConcept C2781303535 @default.
• W3136806177 hasConcept C502942594 @default.
• W3136806177 hasConcept C71924100 @default.
• W3136806177 hasConcept C98274493 @default.
• W3136806177 hasConceptScore W3136806177C102652120 @default.
• W3136806177 hasConceptScore W3136806177C136229726 @default.
• W3136806177 hasConceptScore W3136806177C141071460 @default.
• W3136806177 hasConceptScore W3136806177C15083742 @default.
• W3136806177 hasConceptScore W3136806177C155672457 @default.
• W3136806177 hasConceptScore W3136806177C171250308 @default.
• W3136806177 hasConceptScore W3136806177C185154212 @default.
• W3136806177 hasConceptScore W3136806177C192562407 @default.
• W3136806177 hasConceptScore W3136806177C19831878 @default.
• W3136806177 hasConceptScore W3136806177C2776694085 @default.
• W3136806177 hasConceptScore W3136806177C2779820397 @default.
• W3136806177 hasConceptScore W3136806177C2780035454 @default.
• W3136806177 hasConceptScore W3136806177C2781303535 @default.
• W3136806177 hasConceptScore W3136806177C502942594 @default.
• W3136806177 hasConceptScore W3136806177C71924100 @default.
• W3136806177 hasConceptScore W3136806177C98274493 @default.
• W3136806177 hasFunder F4320321006 @default.
• W3136806177 hasFunder F4320322482 @default.

• next